Parameter
| Biomarker | Tregs/eTregs | Full name | Regulatory T cells/effector Regulatory T cells | Molecular Type | Immunocyte |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Monitoring and prognosis of treatment-free response (TFR) |
| Disease | Chronic Myeloid Leukemia(CML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Clinical samples (flow cytometry) | ||
| Pathobiological Mechanisms | Maintaining TFR, with a transient increase in eTregs after discontinuation followed by return to baseline, and CD8(+) T cells in an activated state. | ||||
| Clinical Availability Status | Research validation: Characteristic changes were observed in patients with 3-year TFR maintenance. | ||||
| Notes and Dynamics | As a biomarker for TFR, high concentrations of imatinib exposure may exert immunosuppressive effects. | ||||